Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000665478 | SCV000789608 | uncertain significance | Alstrom syndrome | 2017-02-14 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000665478 | SCV001609669 | likely benign | Alstrom syndrome | 2024-01-08 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001553714 | SCV001774691 | uncertain significance | not specified | 2021-07-12 | criteria provided, single submitter | clinical testing | Variant summary: ALMS1 c.9905-13C>T alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. The variant allele was found at a frequency of 5.6e-05 in 249026 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in ALMS1 causing Alstrom Syndrome With Dilated Cardiomyopathy (5.6e-05 vs 0.0018), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.9905-13C>T in individuals affected with Alstrom Syndrome With Dilated Cardiomyopathy and no experimental evidence demonstrating its impact on protein function have been reported. Co-occurrence with another pathogenic variant has been reported (internal specimen, MYH7 c.2722C>G), providing supporting evidence for a benign role. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as likely benign, and one laboratory classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |